Interventional cardiologists perform world’s first TAVR with new embolic protection device
The device, designed with improved filtration and stability in mind, is now being investigated as part of a new pilot study.
Related Articles
A new use for IVL: helping cardiologists secure transcarotid access for TAVR
IVL can do more than help prep patients for PCI. In fact, one heart team used Shockwave Medical’s IVL technology to secure access for a…
TAVR and SAVR deliver similar outcomes for patients with low-flow, low-gradient aortic stenosis
Paravalvular leak was more common after TAVR, as one may expect, but that was the only notable difference between the two aortic valve replacement strategies.…
Cardiologists are first in world to use new cooling device to terminate AFib during surgery
Patients often develop AFib during cardiac surgery, leading to longer hospital stays, additional healthcare costs and a higher risk of mortality. Cooling the oblique sinus of…
Rates of obesity, high blood pressure and diabetes keep climbing in US
As time goes on, the gaps between the healthiest states and the least healthy states are only getting wider and wider. “Our findings highlight the…
AI-enabled CCTA evaluations reduce use of invasive imaging exams
This two-year analysis of the FISH&CHIPS study found that using advanced AI from Heartflow to evaluate cardiac CT is safe, effective and limits the use…
High Lp(a) levels increase risk of repeat cardiovascular events—LDL drugs may help
Researchers evaluated data from more than 273,000 patients with a history of ASCVD, noting that higher Lp(a) levels are consistently linked to worse cardiovascular outcomes.
Smaller LV dimensions may increase risk of death for HeartMate 3 LVAD patients
Researchers tracked short- and long-term data from nearly 2,000 patients, presenting their findings in JACC: Heart Failure.
Answering key follow-up questions after the FDA approved TAVR in asymptomatic patients
The approval of certain TAVR valves to be used in asymptomatic patients is expected to make a significant impact on patient care going forward.
Stenting ‘an important treatment option’ for PCI patients with complete blockages
The study’s lead author emphasized that stenting during CTO PCI procedures “should be considered safe and effective in the long term.”
Integrating Barostim into a Comprehensive Heart Failure Program: How Duke Is Improving Outcomes & Navigating Reimbursement Challenges
Duke University Health System has integrated Barostim into its comprehensive heart failure program. For patients with heart failure with reduced ejection fraction (HFrEF), Barostim is…